Alfonso Gómez de Liaño/X
Jun 1, 2025, 06:27
Alfonso Gómez de Liaño Highlights CREST Trial Insights in BCG-Unexposed Bladder Cancer at ASCO 2025
Alfonso Gómez de Liaño, Medical Oncologist at the Insular-Materno Infantil University Hospital Complex, posted on X:
“ASCO25 CREST (sasanlimab + BCG ) show consistent EFS benefit across stages. Sankey plots show benefit driven mainly in NMIBC recurrence but PS seems similar between arms.
Is IO ready for prime time in BCG unexposed BC?”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 12:08
Aug 5, 2025, 11:41
Aug 5, 2025, 11:31
Aug 5, 2025, 11:29
Aug 5, 2025, 11:18